ARF6 Promotes the Formation of Rac1 and WAVE-Dependent Ventral F-Actin Rosettes in Breast Cancer Cells in Response to Epidermal Growth Factor

Valentina Marchesin1,2, Guillaume Montagnac1,2*, Philippe Chavrier1,2*

1 Institut Curie, Research Center, 75005 Paris, France, 2 Membrane and Cytoskeleton Dynamics, Centre National de la Recherche Scientifique UMR144, 75005 Paris, France

* Current address: Institut Gustave Roussy, Inserm U1009, Villejuif, France

* philippe.chavrier@curie.fr

Abstract

Coordination between actin cytoskeleton assembly and localized polarization of intracellular trafficking routes is crucial for cancer cell migration. ARF6 has been implicated in the endocytic recycling of surface receptors and membrane components and in actin cytoskeleton remodeling. Here we show that overexpression of an ARF6 fast-cycling mutant in MDA-MB-231 breast cancer-derived cells to mimic ARF6 hyperactivation observed in invasive breast tumors induced a striking rearrangement of the actin cytoskeleton at the ventral cell surface. This phenotype consisted in the formation of dynamic actin-based podosome rosette-like structures expanding outward as wave positive for F-actin and actin cytoskeleton regulatory components including cortactin, Arp2/3 and SCAR/WAVE complexes and upstream Rac1 regulator. Ventral rosette-like structures were similarly induced in MDA-MB-231 cells in response to epidermal growth factor (EGF) stimulation and to Rac1 hyperactivation. In addition, interference with ARF6 expression attenuated activation and plasma membrane targeting of Rac1 in response to EGF treatment. Our data suggest a role for ARF6 in linking EGF-receptor signaling to Rac1 recruitment and activation at the plasma membrane to promote breast cancer cell directed migration.

Introduction

Reorganization of the actin cytoskeleton is critical for invasive cell behavior of metastatic cancer cells by generating forces needed to move and to overcome physical resistance of three-dimensional (3D) tissue environment [1, 2]. Cancer cells plated on 2D matrix substrates in vitro form typical plasma membrane protrusive structures including lamellipodia, sheet-like protruding leading edge of migrating cells and invadopodia, ventral degradative protrusions enriched in membrane-type 1 matrix metalloproteinase (MT1-MMPs), the enzyme responsible for pericellular degradation of ECM components [3]. Lamellipodia and invadopodia are
dependent on the assembly of a branched filamentous (F-)actin network and requires activation of the Arp2/3 complex by its upstream activators SCAR/WAVE complex and N-WASP, respectively [4–7]. In addition, growth factors stimulation triggers the formation of highly dynamic actin-based circular dorsal ruffles (CDRs), which propagate as waves along the dorsal plasma membrane. Although their function remains ill-defined, these structures are thought to have a role in fast disassembly and remodeling F-actin prior lamellipodium formation and therefore they may be involved in directed cell motility and internalization of receptor tyrosine kinases (RTKs) and other membrane receptors [8, 9].

The protrusive and migratory potential of invasive tumor cells is enhanced by up-regulation of several genes involved in cell motility including the gene coding for the F-actin binding protein cortactin [10, 11]. In addition, some RTKs such as the epidermal growth factor receptor (EGF-R) have a pro-migratory potential; EGF-R is expressed in carcinoma cells of various origins and it stimulates actin-driven membrane protrusions in response to EGF during chemotactic cell migration [12–14]. EGF-R signaling has been correlated with invasiveness and poor survival in breast cancers [15].

The small GTP-binding protein ADP-ribosylation factor 6 (ARF6) is known to coordinate endocytosis, post-endocytic recycling and actin cytoskeletal organization at the plasma membrane [16, 17]. By controlling recycling of lipids and proteins in the endocytic pathway, ARF6 has been implicated in several cell polarization events including cell migration and cancer invasion. Recent studies suggest a link between up-regulation of ARF6 expression and activity and the invasive capacity of breast cancer cells [18–21]. In human MDA-MB-231 breast adenocarcinoma-derived cells, ARF6 controls invadopodia assembly and the recruitment of invadopodial components cortactin and paxillin through its downstream effector AMAP1 [22]. In addition, ARF6 activation has been linked to EGF signaling via its guanine exchange factor (GEF) GEP100/BRAG2, which interacts with ligand-activated EGF-R [18]. Several studies also showed that ARF6 stimulates actin reorganization and membrane ruffling and promotes the acquisition of a migratory phenotype likely through recycling and activation of the Rho GTPase Rac1 [23–27]. Rac1 promotes actin polymerization during lamellipodia extension by activating the Arp2/3 activator WAVE and by increasing actin monomer availability by regulating cofillin, an F-actin-depolymerization factor [28]. Rac1 is overexpressed or hyperactive in breast tumors [29] and Rac1-GEFs are overexpressed in high-grade poor-prognosis breast tumors [30]. However, ARF6-dependent Rac1 regulation is complex and varies depending on cell types and requires further investigation [27, 31, 32].

In this study we used a gain of function approach to mimic up-regulation of ARF6 activity reported in breast tumor cells and to unravel the mechanism through which ARF6 controls cancer cell migration. In MDA-MB-231 cells, expression of a hyperactive mutant of ARF6 (ARF6T157N) [33, 34] induced a striking rearrangement of the actin cytoskeleton at the ventral cell surface, consisting in the formation of podosome rosette-like structures positive for markers including cortactin, the Arp2/3 complex, the SCAR/WAVE complex and its most prominent regulator Rac1. In addition, we showed that ARF6 silencing inhibits Rac1 activation and targeting to the leading edge in response to EGF treatment, suggesting a role for ARF6 in linking EGF-R signaling to Rac1 recruitment and activation at the plasma membrane.

Materials and Methods

Cell culture

Human breast adenocarcinoma MDA-MB-231 cells (American Type Culture Collection HTB-26) were maintained in L-15 culture medium (Sigma–Aldrich, St. Louis, MO, USA) with 2 mM glutamine (GIBCO) and 15% FBS (GIBCO) at 37°C in 1% CO2.
Immunoblotting analysis

Cells were lysed and proteins were eluted in SDS sample buffer, separated by SDS-PAGE, and detected by immunoblotting analysis with indicated antibodies. Bound antibodies were detected with ECL Western Blotting Detection Reagents (GE Healthcare Life Sciences). Densitometric quantification of bands was performed with Gels tool of ImageJ software (http://rsb.info.nih.gov/ij/).

Antibodies

Antibodies used in this study are listed in S1 Table.

Plasmid constructs and DNA transfection

Full-length rat cortactin cDNA subcloned in pDsRed1-N1 or pEGFP-N1 (Clonetech) were provided by Dr M.A. McNiven (Mayo Clinic, Rochester, MI, USA). cDNA encoding ARF6T157N (a gift from Dr M. Franco, Univ Sophia-Antipolis, France) was inserted in a pDEST WPI lentiviral expression vector (a kind gift from P. Benaroch, Institut Curie, Paris) through Gateway Cloning technology (Invitrogen). C-terminally GFP-tagged ARF6T157N construct was obtained by subcloning ARF6T157N cDNA into a pEGFP-N1 vector (Clontech). N-terminally-GFP tagged Rac1G12V was a gift from P. Fort (CRBM, Montpellier, France). For transient expression, MDA-MB-231 cells were transfected with plasmid constructs (1 μg) by using Lipofectamine LTX (Invitrogen) or Nucleofector (Lonza) according to the manufacturer’s instructions. Cells were analyzed 48 h after transfection.

Protein purification and pull-down assay

pGEX constructs encoding GST or the residues 371–507 (LZII domain) of human JIP3 fused with an amino-terminal GST moiety [35] were purified as described [35]. MDA-MB-231 cells or MDA-MB-231 cells stably overexpressing ARF6 wild-type, ARF6T27N or ARF6T157N were lysed in 50 mM Tris pH 7.4, 137 mM NaCl, 10 mM MgCl2, 10% glycerol, 1% Triton-X100 and a cocktail of protease inhibitors (Roche) and centrifuged at 15,000g for 15 min at 4°C. Supernatants were incubated with GST (20 μg/reaction) or GST–LZII (37 μg/reaction) for 15 min at 4°C in the presence of 0.5% BSA. Then, glutathione-Sepharose beads were added for 1 h at 4°C. Beads were washed and bound proteins were analyzed by SDS–PAGE and immunoblotting using anti-ARF6 monoclonal antibody.

siRNA treatment and lentiviral transduction for protein expression

siRNA transfection was performed using 50 nM siRNA with Lullaby reagent (OZ Biosciences) according to manufacturer’s instructions and analyzed 72 hrs after treatment. The siRNAs used in this study are listed in S2 Table.

For lentivirus production, HEK293T cells were transfected using GeneJuice (Novagen) with a mix of ARF6-T157N expression vector and psPAX2 (AddGene) and pVSV-G (Clonetech) packaging vectors in OPTIMEM (Invitrogen). After 72 hrs, virus-containing supernatant was collected, filtered and used for transduction of a subconfluent monolayer of MDA-MB-231 cells.

Indirect immunofluorescence and epifluorescence microscopy

MDA-MB-231 cells stably expressing ARF6T15TN were cultured on gelatin-coated coverslips prepared as described [36]. Cells were permeabilized with 0.5% Triton-X100 and 4% PFA in PBS for 90 seconds, fixed in 4% PFA in PBS and stained with indicated antibodies. For
β1-integrin staining cells were fixed in 4% PFA in PBS and permeabilized with 0.05% saponin in PBS. For Rac1 staining MDA-MB-231 cells, cultured on gelatin-coated coverslips, were fixed in 4% PFA in PBS and permeabilized with Triton-X100 0.1% in PFA for 4 min before staining. Cells were imaged with the 60X objective of a wide-field microscope DM6000 B/M (Leica Microsystems) equipped with a CCD CoolSnap HQ camera (Roper Scientific) and steered by Metamorph (Molecular Devices Corp., Sunnyvale, CA).

For quantification of Rac1 recruitment at cell edge, a line of 160 pixels was drawn perpendicularly to the leading edge in a way that half of the line (about 80th pixel) was at the level of the plasma membrane and fluorescence intensity along the line was measured with the Line-scan tool of Metamorph software. Intensity profiles from different cells were then averaged and normalized for the highest value (set to 100).

Fluorescent gelatin degradation assay
MDA-MB-231 cells and cells stably expressing ARF6T157N were incubated for 5 h on FITC-conjugated cross-linked gelatin (Invitrogen), fixed and stained for cortactin [36]. Cells were imaged with the x63 objective of a wide-field microscope DM6000 B/M (Leica Microsystems) equipped with a CCD CoolSnap HQ camera (Roper Scientific) and steered by Metamorph (Molecular Devices Corp., Sunnyvale, CA). For quantification of degradation, the total area of degraded matrix in one field (black pixels) measured with the Threshold command of Metamorph was normalized by the total surface of the cell to define a degradation index. The index was then normalized to the one of control siNT-treated cells set to 100.

Live-cell spinning disk confocal microscopy
MDA-MB-231 cells transiently transfected with DsRed-cortactin and ARF6T15TN-GFP or GFP-Rac1G12V were plated on glass-bottom MatTek dishes coated with cross-linked gelatin and kept in a humidified atmosphere at 37°C and 1% CO2. Formation of cortactin-positive rosettes was monitored by acquiring 3D time-series images by confocal spinning-disk microscopy (1 z-stack/4 or 3 s) using a Nikon Eclipse TE2000-U microscope equipped with a 60x 1.45NA oil immersion objective, a PIFOC Objective stepper, a Yokogawa CSU22 confocal unit and a Roper HQ2 CCD camera steered by Metamorph and a temperature controller. MDA-MB-231 cells stably expressing ARF6T157N and transiently transfected with GFP-cortactin were plated on MatTek dishes layered with a drop of polymerized type I collagen mixed with AlexaFluor 549-conjugated type I collagen (BD) at a final concentration of 2.5 mg/ml. Cells were incubated for 30 min at 37°C in 1% CO2 and then imaged by confocal spinning disk microscopy (2 z-stack/min).

Total interference reflection fluorescence microscopy (TIRFM)
MDA-MB-231 cells stably expressing ARF6T15TN and transiently transfected with DsRed-cortactin were plated on glass-bottom MatTek dishes coated with cross-linked gelatin for two hours before being imaged. MDA-MB-231 cells were depleted with non-targeting or ARF6 siRNAs and transfected with GFP- or DsRed-cortactin, respectively. The two cell populations (red and green) were mixed and plated on gelatin-coated MatTek dishes for two hours and imaged. Simultaneous dual color TIRFM time-lapse sequences were acquired on a Nikon TE2000 inverted microscope equipped with a ×100 TIRF objective (NA = 1.47), a TIRF arm, an image splitter (DV, Roper Scientific) installed in front of the CCD camera and a temperature controller. GFP and DsRed were excited with 491- and 560 nm-lasers, respectively (100 mW, Roper Scientific), controlled for power by an acousto-optic tunable filter. Fluorescent emissions were selected with bandpass and longpass filters (Chroma) and captured by a QuantEM EMCCD
camera (Roper Scientific). The system was driven by Metamorph. Images were acquired with a 1 min interval for several hours. Kymographs were obtained with Metamorph software along a line perpendicular to protruding leading edge. Membrane protrusion speed was calculated by dividing the length of the vertical axis of the kymograph representing the distance of protrusion extension by the time.

For EGF stimulation experiment, MDA-MB-231 cells were transiently transfected with DsRed-cortactin, serum-starved for 16 hours and plated on glass-bottom dishes coated with cross-linked unlabeled gelatin and images were acquired with a 5 sec interval for 1 min before adding EGF (Preprotech), added directly to the medium at 100 ng/mL final concentration.

**EGF stimulation experiments and G-LISA activation assays**

MDA-MB-231 cells were serum starved for 12–16 hours and EGF was added at 100 ng/mL final concentration for the indicated times. Cells were transferred on ice and immediately permeabilized with 0.5% Triton-X100 in 4% PFA in PBS for 90 seconds, fixed in 4% PFA in PBS and stained for cortactin. For measuring ARF6 and Rac1 activation levels, we used G-LISA-ARF6 Activation Assay kit (Cytoskeleton Inc, BK133) and G-LISA-Rac1 Activation Assay kit (Cytoskeleton Inc, BK126). MDA-MB-231 cells were treated with the indicated siR-NAs for 72 hours, plated on gelatin-coated wells of a 6-well plate, serum starved and EGF-stimulated as described above. EGF stimulation was blocked on ice and cells were immediately lysed with lysis buffer and processed following the manufacturer’s instructions. Briefly the G-LISA kits contain an ARF6- or Rac1-GTP-binding protein linked to the wells of a 96 well plate. Active, GTP-bound ARF6 or Rac1 in cell lysates bind to the wells while the inactive GDP-bound form is removed during washing steps. Active bound ARF6 or Rac1 were detected with ARF6 or Rac1 specific antibodies and the signal is developed with HRP detection reagents following manufacturer’s instructions.

**Statistics**

Statistical analyses were performed using Student’s or Mann-Whitney t-test two-way ANOVA and Spearman correlation test using GraphPad Prism (GraphPad Software) as specified in each figure legend with \( p < 0.05 \) considered significant.

**Results and Discussion**

MDA-MB-231 cells stably expressing a fast-cycling mutant of ARF6 (ARF6T157N) were generated by lentiviral transduction. This mutant is characterized by increased spontaneous GDP dissociation and GTP association [34], thus mimicking the effect of hyperactivation of ARF6 due to reported up-regulation of GEP100/BRAG2 ARF6-GEF in highly aggressive breast carcinoma cells [18]. As assessed by pull-down assay using the ARF6-binding domain of JIP3 protein [35], stable expression of ARF6T157N resulted in a ~4-fold increase in GTP-ARF6 levels in MDA-MB-231 cells, while expression of ARF6T27N correlated with almost undetectable GTP-ARF6 levels in agreement with the dominant inhibitory potential of this variant (S1 Fig.).

MDA-MB-231 cells stably expressing ARF6T157N were plated on a 2D substrate of cross-linked gelatin [37] and stained for F-actin and F-actin-binding protein cortactin. Both in ARF6T157N-expressing cells and parental MDA-MB-231 cells, F-actin and cortactin accumulated in peripheral lamellipodia (Fig. 1A, arrows) and in cytoplasmic dot-like structures (Fig. 1A, asterisks) corresponding to F-actin/cortactin double-positive puncta associated with endocytic compartments [38]. ARF6T157N-expressing cells, displayed increased number of cortactin-positive peripheral lamellipodia (Fig. 1A, arrows). In addition, we observed a striking accumulation of F-actin and cortactin in podosome rosette-like structures forming at the
Fig 1. Hyperactivation of ARF6 induces formation of ventral self-expanding F-actin and cortactin-rich rosette-like structures in MDA-MB-231 breast adenocarcinoma cells. (A) Immunofluorescence microscopy micrographs of MDA-MB-231 cells (left panel) or MDA-MB-231 cells stably expressing ARF6T157N (upper right panel) or ARF6T27N (lower right panel) stained for cortactin. Arrowheads, ventral cortactin-positive rosettes; arrows, cortactin-enriched lamellipodia; asterisks, endosomal cortactin-rich puncta. Scale bar, 5 μm. (B) Percentage of cells displaying cortactin-positive rosettes.

MDA-MB-231/ARF6T157N - DsRed-cortactin

1 min

15 min

MDA-MB-231/ARF6T157N-GFP cortactin-DsRed

148 s

ARF6T157N-GFP
cortactin-DsRed

Merge

ARF6 Control Actin-Based Rosette Formation in Breast Cancer Cells
ventral cell surface (Fig. 1A and S2 Fig.). Rosette formation occurred in ~50% of the cells as compared to only 14% in parental MDA-MB-231 cells (Fig. 1B). In contrast, expression of dominant inhibitory ARF6T27N led to a 40–50% reduction of cells forming podosome rosettes (Fig. 1AB).

By live-cell imaging by TIRF microscopy (TIRFM) we confirmed that cortactin-positive rosettes occurred ventrally and were highly dynamic, expanding outward as waves and then disassembling in a few minutes (Fig. 1C and S1 Video). When these structures formed in proximity to the cell edge, they often merged with the peripheral plasma membrane (Fig. 1D and S2 Video). This observation, together with the increased number of cortactin-positive peripheral lamellipodia observed in fixed samples (Fig. 1A, arrows) led us to hypothesize an implication for these structures in lamellipodium formation. In agreement with this hypothesis the projected surface area of ARF6T157N-expressing cells was larger (3163 ± 102 μm², scoring 25 cells) than that of parental cells (1654 ± 83 μm², scoring 23 cells) suggesting that activated ARF6-induced cortactin-rich rosettes contribute to cell spreading. c-Src protein Tyrosine-kinase and phosphorylated-tyrosine residues (S2 Fig.) as well as focal adhesion proteins paxillin, vinculin and β1-integrin (S2 Fig.) were associated with cortactin-rich rosettes, suggesting a link with cell adhesion. This assumption was supported by the observation that when MDA-MB-231/ARF6T157N cells were seeded atop of a layer of fibrillar type I collagen, recruitment of cortactin occurred in linear structures forming in association with the underlying collagen fibril and then expanded outwardly as a wave (S2 Fig. and S3 Video). Dynamics of C-terminally GFP-tagged ARF6T157N and cortactin-DsRed were analyzed by dual-color confocal spinning-disk microscopy in MDA-MB-231 cells (Fig. 1E and S4 Video). Focal accumulation of ARF6T157N-GFP occurred at the ventral plasma membrane and grew outward as a self-propagating wave within the plane of the plasma membrane. Live cell imaging and kymograph analysis revealed that a front wave of ARF6T157N preceded a back wave of F-actin/cortactin polymerization (Fig. 1F,G).

A role for ARF6 in lamellipodia extension was addressed by following the dynamics of cortactin-enriched rosettes in MDA-MB-231 cells by TIRFM (Fig. 2A). In control cells treated with an irrelevant non-targeting siRNA sequence (siNT), ventral rosettes formed in proximity of plasma membrane edge protrusions with a frequency of ~1.7 rosette/hr; silencing of ARF6 drastically decreased rosette formation frequency (Fig. 2AB and S5 Video). Similarly, silencing of ARF6 reduced the frequency of plasma membrane protrusions (Fig. 2C) suggesting a correlation between occurrence of the two structures. Indeed, a positive correlation was observed between the number of rosettes and protrusions forming per cell (Fig. 2D). Finally, kymograph analysis showed that in cells depleted for ARF6, plasma membrane protruded at reduced speed as compared to siNT-treated cells (Fig. 2EF and S6 Video). All together, these data suggest that ARF6-dependent ventral rosettes play a role in membrane protrusions formation and cell motility in MDA-MB-231 breast cancer cells.

The presence of invadopodia-promoting c-Src and phosphorylated-tyrosine residues in podosome-like rosettes (S2 Fig.), together with their morphological similarity with podosomes...
Fig 2. Cortactin-rich rosettes are ARF6-dependent and correlate with membrane protrusion formation. (A) Still images of TIRFM time-lapse sequences of MDA-MB-231 cells treated with non-targeting or ARF6 siRNAs and transfected with GFP- or DsRed-cortactin, respectively. Arrowheads, ventral cortactin-positive rosettes; arrows, cortactin-enriched lamellipodia. Scale bars, 10 μm. (B-C) Frequency of cortactin-positive rosette (B) and membrane protrusion formation (C) in the indicated cell populations was calculated by scoring rosettes or protrusions occurring per cell and per hour. Values
in Src-transformed cells [39, 40] suggested that ARF6T157N-induced rosettes may represent some type of matrix degradative structures. However, in contrast to bona fide invadopodia forming at the ventral plasma membrane of MDA-MB-231 cells plated on fluorescently labeled gelatin (Fig. 2G), gelatin degradation was not associated with ventral cortactin-positive rosettes in MDA-MB-231/ARF6T157N cells (Fig. 2H). In addition, the percentage of MDA-MB-231/ARF6T157N cells able to degrade gelatin was decreased by 40% as compared to parental MDA-MB-231 cells (Fig. 2I). Of note, a subset of degradative ARF6T157N-expressing cells (~25%) were associated with extensive diffused gelatin degradation (Fig. 2I), contrasting with typical focal invadopodia-mediated degradation in MDA-MB-231 cells (Fig. 2G). Consequently, the degradation index of ARF6T157N-expressing cells increased as compared to parental MDA-MB-231 cells although not significantly (Fig. 2K). Therefore, although we do not exclude the possibility that ventral rosettes may have some degradative capacity, our data rather suggest that because of high intrinsic dynamics, ARF6T157N-induced podosome-like rosettes cannot mediate efficient matrix degradation in contrast to classical long-lasting invadopodia (lifetime > 1 hr, see [41]).

We then sought to identify the molecular pathway involved in cortactin-rich rosette formation. We observed that ventral rosettes in MDA-MB-231/ARF6T157N cells were positive for the p34-Arc subunit of the actin-nucleating Arp2/3 complex (Fig. 3A), suggesting that they depend on the branched-dendritic actin machinery for their formation. We investigated the distribution of nucleation promoting factors (NPFs) known to activate the Arp2/3 complex i.e. WASP family proteins N-WASP, SCAR/WAVE and WASH. WAVE2, a subunit of the SCAR/WAVE complex, showed the strongest co-localization with these structures (Fig. 3B). N-WASP was also present in cortactin-positive rosettes (Fig. 3C). On the contrary, WASH was not detected in ventral rosettes in MDA-MB-231/ARF6T157N cells while it was associated with cortactin-positive endosomal puncta in the central cell region (Fig. 3D).

The contribution of these different proteins to rosette formation was assessed by siRNA-based silencing (S3 Fig.). Silencing of the p34-Arc subunit of Arp2/3 complex subunit dramatically decreased the percentage of cells displaying cortactin-rossettes (Fig. 3EF). Knockdown of WAVE2 with two independent siRNAs decreased rosette formation (Fig. 3EF). Pentameric SCAR/WAVE complex exists in several variants and three distinct WAVE subunit isoforms can assemble into different complexes [42]. Knockdown of Nap1, a common subunit to all SCAR/WAVE complexes, resulted in drastic inhibition of cortactin-positive rosettes formation (Fig. 3EF). Given the prominent role of SCAR/WAVE in lamellipodia regulation and cell motility downstream of Rac [43–46], these data suggested a role for ARF6 as an upstream regulator of the SCAR/WAVE complex and therefore of lamellipodia formation in breast cancer cells. In agreement with localization data, WASH knockdown did not cause any significant effect, while silencing of N-WASP decreased the percentage of cells displaying cortactin-positive
Fig 3. Formation of cortactin-positive ventral rosettes requires the Arp2/3 complex and SCAR/WAVE. (A-D) MDA-MB-231 cells stably expressing ARF6T157N plated on cross-linked gelatin were fixed and stained for the indicated proteins. Images were acquired by wide-field microscopy. Scale bar, 10 μm. Insets are higher magnification of the boxed regions. Scale bar 5 μm. (E) Cells stably expressing ARF6T157N treated with the indicated siRNAs for 72 hours were plated on cross-linked gelatin, fixed and stained for cortactin. Scale bar, 10 μm. (F) The percentage of cells displaying cortactin-positive rosettes...
rosettes from 50% in control cells to 20% suggesting a possible implication of N-WASP in ventral rosette formation downstream of activated ARF6 (Fig. 3EF). These findings are compatible with the reported localization of N-WASP in lamellipodia in carcinoma cells [5] and with a possible role for N-WASP in lamellipodia regulation [7]. Finally, inhibition of rosette formation in cells silenced for the Arp2/3 complex or SCAR/WAVE and N-WASP NPFs correlated with a strong decrease in cell area (see Fig. 3E), in agreement with a role for ARF6-mediated rosette formation in lamellipodia extension and cell spreading and adhesion.

Since EGF-R signaling has been implicated in the formation of migratory protrusions, such as lamellipodia and CDRs [8, 13, 27] and in ARF6 activation [18], we investigated whether EGF treatment could result in rosette formation in serum-starved MDA-MB-231 cells. Using wide-field fluorescence microscopy, we observed a rearrangement of cortactin distribution already 30 sec-2 min after EGF stimulation and formation of cortactin-positive rosettes was visible in up to 40% of the cells after 5–10 min (Fig. 4AB). Using TIRFM, we confirmed that EGF-induced rosettes occurred at the ventral cell surface (Fig. 4C and S7 Video) with similar morphology and dynamics as compared to ARF6T157N-induced structures.

These data suggested that EGF-R triggers the formation of cortactin-rich ventral rosettes through activation of ARF6 that could be mimicked by expression of the fast-cycling ARF6T157N variant. Thus, we hypothesized that in breast cancer cells, ARF6 could be activated downstream of EGF-R signaling and activates SCAR/WAVE and Arp2/3 complexes with a potential regulatory role in leading edge extension and adhesion to the ECM. As Rac1 is the most prominent activator of the SCAR/WAVE complex and because ARF6 has been reported to regulate Rac1 activation, we looked at a possible regulation of Rac1 by ARF6 in MDA-MB-231 cells. We observed that in MDA-MB-231 cells stably expressing ARF6T157N, Rac1 colocalized with ventral cortactin-positive rosettes (Fig. 5A) and levels of active GTP-bound Rac1 increased by 50% as compared to control cells (S4 Fig.). Moreover expression of constitutively active GFP-tagged form of Rac1 (Rac1GV12) in MDA-MB-231 triggered formation of ventral cortactin-positive rosettes (S4 Fig. and S8 Video) similar to those induced upon expression of ARF6T157N or EGF treatment. All together, these observations suggested that Rac1 activation is required for cortactin-positive rosette formation downstream of ARF6. Along this line, we investigated a potential role of ARF6 in spatial polarization of Rac1 distribution by silencing ARF6 in MDA-MB-231 cells (Fig. 5B). By immunofluorescence staining we observed that EGF stimulation of MDA-MB-231 cells for 15 minutes induced increased lamellipodial recruitment of Rac1 and F-actin (Fig. 5C, upper panels). F-actin- and Rac1-enriched rosettes were also visible although they were mainly peripheral after 15 minutes of EGF stimulation (Fig. 5C, arrowheads). In contrast, silencing of ARF6 resulted in a 50% reduction of lamellipodial recruitment of Rac1 and inhibition of lamellipodia formation (Fig. 5C,D). Based on these data, we propose that ARF6 regulates localized targeting and activation of Rac1 to the leading edge of breast cancer cells where in turn, activated Rac1 triggers lamellipodial actin polymerization. We used ARF6 and Rac1 G-LISA activation assays to monitor the activation level of both GTP-binding proteins under EGF stimulation of serum-starved MDA-MB-231 cells. Both ARF6 (Fig. 5E, blue bars) and Rac1 activation levels (Fig. 5E, purple bars) increased by 1 min and further by 15 min EGF treatment. Moreover, silencing of ARF6 decreased by six-fold the level of GTP-Rac1 both in non-stimulated condition and in response to EGF stimulation and abolished EGF-induced Rac1 activation (Fig. 5E). All together, these findings strongly suggest that ARF6 is required for Rac1 activation and localization.
Fig 4. EGF stimulation triggers the formation of ventral F-actin structures in MDA-MB-231 cells. (A) MDA-MB-231 cells were plated on cross-linked gelatin, serum starved over-night and stimulated with EGF for 30’ sec up to 10 min as indicated. Then cells were fixed and stained for cortactin and images were acquired by wide-field microscopy. Arrows point to nascent cortactin-positive rosettes. Scale bar, 10 μm. (B) MDA-MB-231 cells were treated as in A and the percentage of cells displaying cortactin-positive rosettes was scored. Values are mean ± SEM from duplicate samples in two independent
Although it is not clear how ARF6 controls Rac1 activation, our findings indicate that in breast cancer cells, ARF6 regulates Rac1 association to the leading edge, possibly involving a Rac1-GEF and that in absence of ARF6, EGF-mediated localization and activation of Rac1 cannot take place. These data are in agreement with a previous study in HeLa cells showing that Rac1 and its GEF, TIAM1 are internalized into early endosomes and activated Rac1 is recycled to dynamic regions of the plasma membrane in response to hepatocyte growth factor in an ARF6-dependent manner leading to the formation of CDRs [27]. One possibility is that cortactin ventral structures we described could play a role similar to CDRs in actin remodeling for lamellipodia formation and ARF6 could be involved in directed cell motility by controlling the formation of these dynamic actin-based structures depending on specific growth factor receptors through localized activation of Rac1 at the ventral or dorsal plasma membrane.

Recent reports have also described ventral F-actin-based waves in several cell types including Dictyostelium discoideum [47]. In neutrophils, Nap1-positive actin propagating waves are thought to play a role in spatial organization and protrusion of the leading edge during cell motility [48]. Fibroblast and human osteosarcoma cells also exhibit ventral F-actin waves positive for Arp2/3 complex, β1-integrin, paxillin, vinculin and other adhesive proteins such as talin and zyxin that propagate as spots and wave-fronts along the ventral plasma membrane and are thought to play a role in coupling ventral actin polymerization and cycles of integrin adhesion/de-adhesion to the ECM [49]. The present study documents the existence of actin dynamic waves in highly aggressive breast cancer cells and points to ARF6 as a master regulator of wave-like structures. A recent report also demonstrated that expression of active mutant forms of ARF1 or ARF6 triggers formation of ventral F-actin waves in epithelial HeLa and Beas-2b cell lines [50]. Induction of these structures was blocked by PKC and c-Src inhibitors and required PI(4,5)P2 [50]. Our observations extend these data by showing that ARF6-induced F-actin ventral rosettes are coupled with plasma membrane protrusions and lamellipodia extension in response to EGF with potential contribution to breast cancer cell motility and matrix remodeling, two essential arms of the metastatic program. In addition, we identified the SCAR/WAVE complex known to control lamellipodia formation, as an essential component of ARF6-mediated rosette formation downstream of Rac1 localization and activation. Along this line, a cascade linking ARF6 and ARF1 in the activation of the SCAR/WAVE complex has been recently reported [51].

Conclusion

Our study provides further evidence for the known activation and plasma membrane localization of Rac1 by ARF6 [23–27] in breast cancers, suggesting a potential contribution for this pathway during the invasive process. Several questions remain unsolved such as how actin wave can propagate in response to wave of ARF6 activity on the ventral plasma membrane, and whether EGF-R signaling is required only for initiation of ventral ARF6/actin waves or if it must be sustained for wave-front propagation. Future studies will be required to decipher the underlying mechanism and function of ARF6-dependent actin waves and their importance for breast cancer cell migration.
Fig 5. Rac1 localizes in ventral actin-rich rosettes and ARF6 is required for Rac1 activation and recruitment. (A) MDA-MB-231 cells stably expressing ARF6T157N were plated on cross-linked gelatin, fixed and stained for F-actin and Rac1. Upper insets are higher magnifications of boxed regions. Lower insets show rosettes from another cell. Scale bars, 10 μm and 5 μm (insets). (B) ARF6 immunoblotting analysis of MDA-MB-231 cell lysates after indicated siRNA treatments. Anti-β-actin was used as loading control. (C) MDA-MB-231 cells were treated with the indicated siRNAs for 72 hours, plated on gelatin and ARF6 Control Actin-Based Rosette Formation in Breast Cancer Cells

PLOS ONE | DOI:10.1371/journal.pone.0121747 March 23, 2015 14 / 19
Supporting Information

**S1 Fig. Stable expression of ARF6T157N results in increased GTP-ARF6 levels in MDA-MB-231 cells.** (A-B) MDA-MB-231 cells were stably transduced with lentiviral vectors expressing the indicated ARF6 variants. Cells lysates were incubated with GST alone or GST fused with the ARF6-binding domain (LZII, leucine zipper II domain) of human JIP3 (aa 371–507), which interacts specifically with GTP-bound ARF6. Immunoblotting analysis of ARF6 in the bound (GTP:ARF6) and input fractions. α-tubulin was used as a loading control. (B) Den- sitometric quantification of ARF6 bands in panel A. Values represent GTP:ARF6 levels after normalization to total ARF6 and α-tubulin levels. (TIF)

**S2 Fig. Ventral cortactin-positive rosettes are positive for invadopodia markers and ECM adhesion proteins.** (A-C) MDA-MB-231 cells stably expressing ARF6T157N were plated on cross-linked gelatin, fixed and stained for the indicated markers. Images were acquired with epifluorescence microscopy. Insets are magnification of the boxed regions. Scale bars, 10 μm and 5 μm (insets). (D) Still image of a confocal spinning-disk microscopy time-lapse sequence of MDA-MB-231 cells stably expressing ARF6T157N plated on a layer of Alexa-546-conjugated type I collagen fibers (red). Cells were transiently transfected with GFP-cortactin (green). Scale bar, 10 μm. The gallery corresponds to the boxed region in the still image and show a cortactin–positive rosette (arrows) forming in association with a collagen I fiber and propagating as a wave. Time is in min. Scale bar, 5 μm. (TIF)

**S3 Fig. Immunoblotting analysis of siRNA-treated cells.** (A-E) Immunoblotting analysis of lysates of MDA-MB-231 cells stably expressing ARF6T157N treated with indicated siRNAs for 72 hrs. Antibodies are indicated on the right. Immunoblotting analysis with anti-α tubulin and anti β1-integrin was used as loading control. Asterisk in A indicates WASH-specific band. (A’-E’) Densitometric quantification of bands in panels A-E. Values represent mean ± SEM of density levels of each protein normalized for β1-integrin (A’-D’) or α-tubulin (E’) density values from four (A’ and C) and three (B’, D’ and E’) independent experiments. Comparisons were made with a Student’s t-test. ***, P < 0.001, **, P < 0.01, *, P < 0.05 (compared to siNT-treated cells). (TIF)

**S4 Fig. Induction of cortactin-positive rosette by constitutively activated Rac1.** (A) GTP: Rac1 levels were compared in MDA-MB-231 cells vs. cells stably expressing ARF6T157N. Values are normalized mean ± SEM from replicate samples. Comparison was made with a Student’s t-test. *, P < 0.05 (compared to MDA-MB-231 cells). (B-C) Still image (B) and gallery (panel C, corresponding to the boxed region in B) of a time-lapse sequence of a MDA-MB-231 cell transiently expressing Rac1G12V-GFP and cortactin-DsRed plated on cross-linked gelatin and imaged with confocal spinning disk microscopy. Scale bar, 10 μm. The gallery corresponds then serum-starved for 12–16 hrs. After 15 min treatment with EGF, cells were fixed and stained for F-actin and Rac1. Insets are higher magnification of boxed regions. Scale bars, 10 μm. Arrowheads, peripheral F-actin-rich rosette. (D) Quantification of Rac1 fluorescence intensity profile was done along a 160-pixel line drawn perpendicularly to the cell edge as shown in insets. Intensity profiles along the line from at least 50 cells per condition from two independent experiments were averaged and normalized to the highest fluorescence intensity value in the siNT-treated cells. Comparison between the two mean peak values (corresponding to the cell edge) was made with a two-way ANOVA test. ****, P < 0.001 (compared to siNT-treated cells). (E) MDA-MB-231 cells were treated with the indicated siRNAs for 72 hrs, plated on gelatin, serum-starved and treated with EGF for 1 or 15 min. Levels of GTP-bound ARF6 (blue bars) and Rac1 (purple bars) in the different conditions were measured with G-LISA assay. Values are normalized mean ± SEM from replicate samples from two independent experiments. Comparisons were made with a Student’s t-test. **, P < 0.01, ***, P < 0.001 (compared with siNT-treated cells).

doi:10.1371/journal.pone.0121747.g005
to the boxed region of the still image and shows formation of cortactin-positive rosettes (red) associated with Rac1G12V-GFP (green). Time is in seconds. Scale bar, 5 μm.

(TIF)

**S1 Table. Antibodies used in this study.** This table provides a list of monoclonal and polyclonal antibodies used in this study, their source and specific use.

(DOCX)

**S2 Table. siRNAs used in this study.** This table provides a list of siRNAs used in this study, their sequence and source.

(DOCX)

**S1 Video. Dynamics of ARF6T157N-induced cortactin-positive ventral rosettes.**
MDA-MB-231 cells stably expressing ARF6T157N and transiently transfected with DsRed-cortactin were plated on unlabeled cross-linked gelatin and imaged by TIRFM (Nikon TE2000 inverted). Images were acquired every minute. Scale bar 10 μm.

(MOV)

**S2 Video. Dynamics of ARF6T157N-induced cortactin-positive rosette located close to the cell edge.** MDA-MB-231 cells stably expressing ARF6T157N and transiently transfected with DsRed-cortactin were plated on cross-linked unlabeled gelatin and imaged by TIRFM (Nikon TE2000 inverted). Images were acquired every minute. Scale bar 10 μm.

(MOV)

**S3 Video. ARF6T157N-induced cortactin-positive ventral rosette forming in association with a type I collagen fibril.** MDA-MB-231 cells stably expressing ARF6T157N and transiently transfected with cortactin-GFP were plated on a layer of Alexa Fluor 549–conjugated collagen I fibrils (red) for 30 min and imaged by confocal spinning disk microscopy (inverted, Nikon Eclipse TE2000-U). Images were acquired every 30 sec. Scale bar 10 μm. The inset is a magnification of the boxed region corresponding to the gallery in S2D Fig.

(MOV)

**S4 Video. Dynamics of ARF6T157N and cortactin in ventral rosette.** MDA-MB-231 cells transiently transfected with DsRed-cortactin (red) and ARF6T157N-GFP (green) were plated on cross-linked gelatin and imaged by confocal spinning disk microscopy (inverted, Nikon Eclipse TE2000-U). Images were acquired every 4 seconds. Scale bar 10 μm. The inset is a magnification of the boxed region and corresponds to the gallery shown in Fig. 1F.

(MOV)

**S5 Video. Dynamics of cortactin-positive ventral rosettes and plasma membrane protrusions in presence or absence of ARF6 in MDA-MB-231 cells.** MDA-MB-231 cells treated with non-targeting (left) or ARF6 (right) siRNAs and transfected with GFP- or DsRed-cortactin, respectively, were mixed, plated on unlabeled cross-linked gelatin and imaged by dual-color TIRFM (Nikon TE2000 inverted). Images were acquired every minute. Scale bar 10 μm.

(MOV)

**S6 Video. Dynamics and speed of plasma membrane protrusions extension in presence or absence of ARF6 in MDA-MB-231 cells.** MDA-MB-231 cells treated with non-targeting (left) or ARF6 (right) siRNAs and transfected with GFP- or DsRed-cortactin, respectively, were mixed, plated on unlabeled cross-linked gelatin and imaged by dual-color TIRFM (Nikon TE2000 inverted). Images were acquired every minute. Scale bar 10 μm.

(MOV)
S7 Video. EGF stimulation triggers the formation of ventral actin structures in MDA-MB-231 cells. Serum-starved MDA-MB-231 cells transiently transfected with DsRed-cortactin were plated on cross-linked gelatin and imaged by TIRFM (Nikon TE2000 inverted). Images were acquired every 5 sec. EGF was added directly in the medium after 1 min of imaging. Scale bar 10 μm. (MOV)

S8 Video. Induction of cortactin-positive ventral rosettes by Rac1G12V. MDA-MB-231 cells transiently transfected with DsRed-cortactin (red) and Rac1G12V-GFP (green) were plated on cross-linked unlabeled gelatin and imaged by confocal spinning disk microscopy (inverted, Nikon Eclipse TE2000-U). Images were acquired every 3 seconds. Scale bar 10 μm. The inset is a magnification of the boxed region and corresponds to the gallery shown in S4C Fig. (MOV)

Acknowledgments
The authors wish to acknowledge Drs M. Franco, G. Scita and A. Gautreau for providing reagents and for helpful discussion and the Nikon Imaging Centre @ Institut Curie-CNRS and Cell and Tissue Imaging Facility of Institut Curie for help with image acquisition.

Author Contributions
Conceived and designed the experiments: VM GM PC. Performed the experiments: VM. Analyzed the data: VM. Wrote the paper: VM PC.

References
1. Albiges-Rizo C, Destaing O, Fourcade B, Planus E, Block MR. Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions. Journal of cell science. 2009; 122(Pt 17):3037–49. doi: 10.1242/jcs.052704 PMID: 19692590
2. Nurnberg A, Kitzing T, Grosse R. Nucleating actin for invasion. Nature reviews Cancer. 2011; 11 (3):177–87. doi: 10.1038/nrc3003 PMID: 21326322
3. Poincloux R, Lizarraga F, Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci. 2009; 122(Pt 17):3015–24. doi: 10.1242/jcs.034561 PMID: 19692588
4. Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, Congioio S, Symons M, et al. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol. 2005; 168(3):441–52. PMID: 15684033
5. Lorenz M, Yamaguchi H, Wang Y, Singer RH, Condeelis J. Imaging sites of N-wasp activity in lamellipodia and invadopodia of carcinoma cells. Curr Biol. 2004; 14(8):697–703. PMID: 15084285
6. Goley ED, Welch MD. The ARP2/3 complex: an actin nucleator comes of age. Nature reviews Molecular cell biology. 2006; 7(10):113–26. PMID: 16990851
7. Campellone KG, Welch MD. A nucleator arms race: cellular control of actin assembly. Nature reviews Molecular cell biology. 2010; 11(4):237–51. doi: 10.1038/nrm2867 PMID: 20237478
8. Buccione R, Orth JD, McNiven MA. Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nat Rev Mol Cell Biol. 2004; 5(8):647–57. PMID: 15366708
9. Orth JD, Krueger EW, Weiler SG, McNiven MA. A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. Cancer Res. 2006; 66(7):3603–10. PMID: 16585185
10. MacGrath SM, Koleske AJ. Cortactin in cell migration and cancer at a glance. Journal of cell science. 2012; 125(Pt 7):1621–6. doi: 10.1242/jcs.093761 PMID: 22966666
11. Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer. 2007; 7(6):429–40. PMID: 17522712
12. Mader CC, Oser M, Magalhaes MA, Bravo-Cordero JJ, Condeelis J, Koleske AJ, et al. An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res. 2011; 71(5):1730–41. doi: 10.1158/0008-5472.CAN-10-1432 PMID: 21257711
13. Chan AY, Raft S, Wyeckoff JB, Segall JE, Condeelis JS. EGF stimulates an increase in actin nucleation and filament number at the leading edge of the lamellipod in mammary adenocarcinoma cells. Journal of cell science. 1998; 111 (Pt 2):199–211. PMID:9405304

14. Desmarais V, Yamaguchi H, Oser M, Soon L, Mouneimne G, Sarmiento C, et al. N-WASP and cortactin are involved in invadopodium-dependent chemotaxis to EGF in breast tumor cells. Cell motility and the cytoskeleton. 2009; 66(6):303–16. doi: 10.1002/cm.20381 PMID:19373774

15. Magkou C, Nakopolou L, Zouboulis C, Karali K, Theokari I, Bakarakos P, et al. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast cancer research: BCR. 2008; 10(3):R49. doi: 10.1186/bcr2103 PMID:18522728

16. D’Souza-Schorey C, Chavrier P. ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol. 2006; 7(5):347–58. PMID:16633337

17. Donaldson JG, Jackson CL. ARF family G proteins and their regulators: roles in membrane transport, development and disease. Nat Rev Mol Cell Biol. 2011; 12(6):362–75. doi:10.1038/nrm3117 PMID:21587297

18. Morishige M, Hashimoto S, Ogawa E, Toda Y, Kotani H, Hirose M, et al. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. Nat Cell Biol. 2008; 10(1):85–92. PMID:18084281

19. Hashimoto S, Onodera Y, Hashimoto A, Tanaka M, Hamaguchi M, Yamada A, et al. Requirement for Arf6 in breast cancer invasive activities. Proceedings of the National Academy of the United States of America. 2004; 101(17):6647–52. PMID:15087504

20. Tague SE, Muralidharan V, D’Souza-Schorey C. ARF6-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc Natl Acad Sci U S A. 2004; 101(26):9671–6. PMID:15210957

21. Li M, Ng SS, Wang J, Lai L, Leung SY, Franco M, et al. EFA6A enhances glioma cell invasion through ADP ribosylation factor 6/extracellular signal-regulated kinase signaling. Cancer Res. 2006; 66(3):1583–90. PMID:16452216

22. Onodera Y, Hashimoto S, Hashimoto A, Morishige M, Mazaki Y, Yamada A, et al. Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. The EMBO Journal. 2005; 24(5):963–73. PMID:15719014

23. Palacios F, D’Souza-Schorey C. Modulation of Rac1 and ARF6 activation during epithelial cell scattering. J Biol Chem. 2003; 278(19):17395–400. PMID:12609992

24. Palacios F, Schweitzer JK, Boshans RL, D’Souza-Schorey C. ARF6-GTP recruits Nm23-H1 to facilitate dynamin-mediated endocytosis during adherens junctions disassembly. Nat Cell Biol. 2002; 4(12):929–36. PMID:12447393

25. Sancy LC, Casanova JE. Activation of ARF6 by ARNO stimulates epithelial cell migration through downstream activation of both Rac1 and phospholipase D. J Cell Biol. 2001; 154(3):599–610. PMID:11481345

26. Sancy LC, Ravichandran KS, Casanova JE. The DOCK180/Elmo complex couples ARNO-mediated Arf6 activation to the downstream activation of Rac1. Curr Biol. 2005; 15(19):1749–54. PMID:16213822

27. Palmaridis A, Frittoli E, Garre M, Faretta M, Mione M, Testa I, et al. Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. Cell. 2008; 134(1):135–47. doi: 10.1016/j.cell.2008.05.034 PMID:18614017

28. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nature reviews Molecular cell biology. 2008; 9(9):690–701. doi:10.1038/nrm2476 PMID:18719708

29. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, et al. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 2000; 19(26):3013–20. PMID:10871853

30. Wertheimer E, Gutierrez-Uzquiza A, Rosemb't C, Lopez-Haber C, Sosa MS, Kazanietz MG. Rac signaling in breast cancer: a tale of GEFs and GAPs. Cellular signalling. 2012; 24(2):353–62. doi: 10.1016/j.cellsig.2011.08.011 PMID:21893191

31. Koo TH, Eipper BA, Donaldson JG. Arf6 recruits the Rac GEF Kalirin to the plasma membrane facilitating Rac activation. BMC cell biology. 2007; 8:29. PMID:17640372

32. Hu B, Shi B, Jarzynka MJ, Yiin JJ, D’Souza-Schorey C, Cheng SY. ADP-ribosylation factor 6 regulates glioma cell invasion through the IQ-domain GTPase-activating protein 1-Rac1-mediated pathway. Cancer research. 2009; 69(3):794–801. doi:10.1158/0008-5472.CAN-08-2110 PMID:19155310

33. Sancy LC. Characterization of a fast cycling ADP-ribosylation factor 6 mutant. J Biol Chem. 2002; 277(43):40185–8. PMID:12218044
34. Klein S, Franco M, Chardin P, Luton F. Role of the Arf6 GDP/GTP cycle and Arf6 GTPase-activating proteins in actin remodeling and intracellular transport. The Journal of biological chemistry. 2006; 281 (18):12352–61. PMID: 16527809

35. Montagnac G, Sibarita JB, Loubey S, Daviet L, Romao M, Raposo G, et al. ARF6 Interacts with JIP4 to control a motor switch mechanism regulating endosome traffic in cytokinesis. Curr Biol. 2009; 19 (3):184–95. doi: 10.1016/j.cub.2008.12.043 PMID: 19211056

36. Sakurai-Yageta M, Recchi C, Le Dez G, Sibarita JB, Daviet L, Camonis J, et al. The interaction of IQGAP1 with the exocyst complex is required for tumor cell invasion downstream of Cdc42 and RhoA. J Cell Biol. 2008; 181(6):985–98. doi: 10.1083/jcb.200709076 PMID: 18541705

37. Artym VV, Zhang Y, Seilier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res. 2006; 66(6):3034–43. PMID: 16540652

38. Monteiro P, Rosse C, Castro-Castro A, Irondelle M, Lagoutte E, Paul-Gilloteaux P, et al. Endosomal WASH and exocyst complexes control exocytosis of MT1-MMP at invadopodia. J Cell Biol. 2013; 203 (6):1063–79. PMID: 24344185

39. Tarone G, Cicillo D, Giancotti FG, Comoglio PM, Marchisio PC. Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. Exp Cell Res. 1985; 159(1):141–57. PMID: 2411576

40. Marchisio PC, Cicillo D, Naldini L, Primavera MV, Teli A, Zambonin-Zallone A. Cell-substratum interaction of cultured avian osteoclasts is mediated by specific adhesion structures. The Journal of cell biology. 1984; 99(5):696–705. PMID: 6436255

41. Lizarra F, Poincloux R, Romao M, Montagnac G, Le Dez G, Bonne I, et al. Diaphanous-related formins are required for invadopodia formation and invasion of breast tumor cells. Cancer Res. 2009; 69 (7):2792–800. doi: 10.1158/0008-5472.CAN-08-3709 PMID: 19276357

42. Soderling SH, Scott JD. WAVE signalling: from biochemistry to biology. Biochemical Society transactions. 2006; 34(Pt 1):73–6.

43. Miki H, Yamaguchi H, Suetsugu S, Takenawa T. IRSp53 is an essential intermediate between Rac and WAVE in the regulation of membrane ruffling. Nature. 2000; 408(6813):732–5. PMID: 11130076

44. Miki H, Suetsugu S, Takenawa T. WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. Embo J. 1998; 17(23):6932–41. PMID: 9843499

45. Suetsugu S, Yamazaki D, Kurisu S, Takenawa T. Differential roles of WAVE1 and WAVE2 in dorsal and peripheral ruffle formation for fibroblast cell migration. Dev Cell. 2003; 5(4):595–609. PMID: 14536061

46. Yan C, Martinez-Quiles N, Eden S, Shibata T, Takeshima F, Shinkura R, et al. WAVE2 deficiency reveals distinct roles in embryogenesis and Rac-mediated actin-based motility. Embo J. 2003; 22 (14):3602–12. PMID: 12853475

47. Bretschneider T, Diez S, Anderson K, Heuser J, Clarke M, Muller-Taubenberger A, et al. Dynamic actin patterns and Arp2/3 assembly at the substrate-attached surface of motile cells. Current biology: CB. 2004; 14(1):1–10. PMID: 14711408

48. Weiner OD, Marganski WA, Wu LF, Altschuler SJ, Kirschner MW. An actin-based wave generator organizes cell motility. PLoS biology. 2007; 5(9):e221. PMID: 17696648

49. Case LB, Waterman CM. Adhesive F-actin waves: a novel integrin-mediated adhesion complex coupled to ventral actin polymerization. PloS one. 2011; 6(11):e26631. doi: 10.1371/journal.pone.0026631 PMID: 22069459

50. Caviton JP, Cohen LA, Donaldson JG. Arf1 and Arf6 promote ventral actin structures formed by acute activation of protein kinase C and Src. Cytoskeleton. 2014; 71(6):380–94. doi: 10.1002/cm.21181 PMID: 24916416

51. Humphreys D, Davidson AC, Hume PJ, Makin LE, Koronakis V. Arf6 coordinates actin assembly through the WAVE complex, a mechanism usurped by Salmonella to invade host cells. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(42):16880–5. doi: 10.1073/pnas.1311680110 PMID: 24085844